PEN

ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026. Revenue of $374.8 million in the first quarter of 2026, an increase of 15.6% compared to the first quarter of 2025. Global thrombectomy revenue of $253.9 million in the first quarter of 2026, an increase of 12.1% compared to the first quarter of 2025. Global embolization and access revenue of $120.8 million in the first quarter of 2026, an increase of 23.8% compared to the first quarter of 2025. Gross profit margin of 67.6% in the first quarter of 2026, an increase of 1.0% compared to the first quarter of 2025. Total operating expenses of $215.2 million in the first quarter of 2026, comprised of R&D of $22.4 million and SG&A of $192.8 million, which includes $9.4 million of acquisition-related expenses associated with the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation. Income from operations of $38.2 million and net income of $32.6 million in the first quarter of 2026. Full Year 2026 Financial Outlook and Webcast and Conference Call Information Given the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be providing financial guidance for the full year 2026 or hosting a conference call to discuss financial results for the three months ended March 31, 2026. About Penumbra Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X. Forward-Looking Statements Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of ri...

Penumbra (PEN) came out with quarterly earnings of $0.82 per share, missing the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.83 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -25.91%. A quarter ago, it was expected that this medical device maker would post earnings of $1.12 per share when it actually produced earnings of $1.18, delivering a surprise of +5.36%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Penumbra, which belongs to the Zacks Medical - Instruments industry, posted revenues of $374.76 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.35%. This compares to year-ago revenues of $324.14 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Penumbra shares have added about 4.2% since the beginning of the year versus the S&P 500's gain of 6%. While Penumbra has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Penumbra was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) st...

ALAMEDA, Calif. (AP) — ALAMEDA, Calif. (AP) — Penumbra Inc. (PEN) on Wednesday reported first-quarter net income of $32.6 million. On a per-share basis, the Alameda, California-based company said it had profit of 82 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of $1.11 per share. The medical device maker posted revenue of $374.8 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PEN at https://www.zacks.com/ap/PEN

Boston Scientific beat expectations in Q1 with organic sales up 9.4%, revenue of $5.203 billion and adjusted EPS of $0.80, while adjusted operating margin was 28%. Management trimmed guidance, cutting full-year organic growth to 6.5–8% and raising full-year adjusted EPS to $3.34–3.41, citing near-term pressure from WATCHMAN, electrophysiology (EP) and Urology (WATCHMAN volumes softened beginning mid‑February). Capital priorities remain strategic tuck‑in M&A and buybacks: the board added $4 billion to reach $5 billion in repurchase authorization with ~$2 billion planned for Q2, the company expects about $4 billion of 2026 free cash flow, and the Penumbra acquisition is still targeted to close in the second half of 2026 pending approvals. Interested in Boston Scientific Corporation? Here are five stocks we like better. Why Boston Scientific's Big Dip Could Be a Bigger Opportunity Boston Scientific (NYSE:BSX) reported first-quarter 2026 results that landed near the top end of management’s prior guidance, while executives reduced their outlook for the remainder of the year citing “unanticipated headwinds” and changing business patterns in several key franchises. Chairman and CEO Mike Mahoney said the company delivered “a solid quarter,” with total company organic sales growth of 9.4% versus a guidance range of 8.5% to 10%. Boston Scientific posted adjusted EPS of $0.80, up 6% year over year and at the high end of its $0.78 to $0.80 range. Adjusted operating margin was 28%. → Credo Stock Flashes Strong Bullish Signal—Upswing Just Starting Beware the Death Cross: 3 Stocks Triggering This Spooky Signal CFO Jon Monson said first-quarter revenue totaled $5.203 billion, representing 11.6% reported growth versus the prior year and including a 220 basis point foreign exchange tailwind ($104 million). Excluding FX, operational and organic revenue growth both came in at 9.4%. On profitability, Monson said adjusted gross margin was 70.5%, down 100 basis points year over year, “primarily driven by tariffs as well as inventory charges related to the discontinuation of our PolarX cryoablation system.” → Allbirds Exits Shoes, Pivots to AI With NewBird Rebrand 3 Healthcare Stocks Using AI to Drive Growth Despite the first-quarter performance, Mahoney said the year “has proven to be a more challenging year than we initially expected,” prompting the company to guide for organic g...

We recently compiled a list of the 10 Best Healthcare Stocks to Buy and Hold for 3 Years. Boston Scientific Corporation is one of the best healthcare stocks. TheFly reported on April 13 that Mizuho reduced its price target on BSX to $90 from $115 while maintaining an Outperform rating. The adjustment was part of a broader update across the firm’s medical devices and diagnostics coverage ahead of upcoming first-quarter earnings. The revisions reflect updated estimates and outlook changes applied across multiple companies within the same sector review. According to a regulatory filing, on March 30, Boston Scientific Corporation (NYSE:BSX) and Penumbra, Inc. each received a “Second Request” from the U.S. Federal Trade Commission as part of its antitrust review of their proposed merger. The request requires both companies to provide additional information, extending the Hart-Scott-Rodino review timeline until 30 days after full compliance, unless modified or concluded earlier by the agency. The filing follows earlier submissions made by both firms in mid-February under standard regulatory procedures. Both companies stated they intend to respond promptly and continue cooperating with the FTC throughout the review process. The extended review period indicates ongoing regulatory scrutiny before any final approval decision is reached. The process is part of the FTC’s standard evaluation of large transactions to assess potential competitive impacts within the healthcare and medical technology sector. Boston Scientific Corporation (NYSE:BSX) is a global medical device company that develops and manufactures minimally invasive medical technologies. It specializes in interventional cardiology, rhythm management, endoscopy, and urology solutions designed to improve patient care and treatment outcomes. While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Healthcare Stocks to Buy and Hold for 3 Years and 10 Best Beaten Down Stocks to Invest in According to Analysts. Disclosure: None. Follow Insider Monkey on Google News.

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including Penumbra (NYSE:PEN) and its peers. The medical devices and supplies industry, particularly in the fields of cardiology, neurology, and vascular care, benefits from a business model that balances innovation with relatively predictable revenue streams. These companies focus on developing life-saving devices such as stents, pacemakers, neurostimulation implants, and vascular access tools, which address critical and often chronic conditions. The recurring need for these devices, coupled with growing global demand for advanced treatments, provides stability and opportunities for long-term growth. However, the industry faces hurdles such as high research and development costs, rigorous regulatory approval processes, and reliance on reimbursement from healthcare systems, which can exert downward pressure on pricing. Looking ahead, the industry is positioned to benefit from tailwinds such as aging populations (which tend to have higher rates of disease) and technological advancements like minimally invasive procedures and connected devices that improve patient monitoring and outcomes. Innovations in robotic-assisted surgery and AI-driven diagnostics are also expected to accelerate adoption and expand treatment capabilities. However, potential headwinds include pricing pressures stemming from value-based care models and continued complexity changing from navigating regulatory frameworks that may prioritize further lowering healthcare costs. The 4 medical devices & supplies - cardiology, neurology, vascular stocks we track reported a strong Q4. As a group, revenues beat analysts’ consensus estimates by 1.5%. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 14% since the latest earnings results. Founded in 2004 to address challenging medical conditions with significant unmet needs, Penumbra (NYSE:PEN) develops and manufactures innovative medical devices for treating vascular diseases and providing immersive healthcare rehabilitation solutions. Penumbra reported revenues of $385.4 million, up 22.1% year on year. This print exceeded analysts’ expectations by 4.8%. Overall, it was an exceptional quarter for the company with an impressive beat of analysts’ revenue and EPS...

It has been about a month since the last earnings report for Penumbra (PEN). Shares have lost about 1.6% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Penumbra due for a breakout? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent catalysts for Penumbra, Inc. before we dive into how investors and analysts have reacted as of late. Penumbra, Inc. (PEN) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.18 compared with 85 cents in the year-ago quarter. The figure surpassed the Zacks Consensus Estimate by 5.36%. GAAP earnings were $1.20 per share compared with 86 cents in the prior-year period. For the full year, adjusted EPS was $3.84, up 82.9% year over year. Penumbra registered revenues of $385.4 million in the reported quarter, up 22.1% year over year on a reported basis and 20.9% at constant exchange rate or CER. The figure topped the Zacks Consensus Estimate by 6.74%. For the full year, revenues were $1.40 billion, reflecting a 17.5% rise from the year-ago period (16.9% at CER). The company reports under two geographical segments — the United States and International. PEN recorded revenues of $299.1 million (77.6% total revenues) in the United States, up 20.6% year over year on a reported basis. Revenues in the International segment increased 27.7% on a reported basis (up 20.9% in CER) to $86.3 million (22.4% of total revenues). The company currently reports its product revenues under two categories — Thrombectomy, and Embolization and Access. The company registered revenues of $254.7 million from sales of Thrombectomy products, up 15.7% on a reported basis and 14.7% at CER. Sales of Embolization and Access products totaled $130.7 million, up 22.1% on a reported basis and 20.9% at CER. In the reported quarter, Penumbra’s gross profit improved 24.4% year over year to $262.1 million. The gross margin expanded 123 basis points (bps) to 68% despite a 17.6% rise in the cost of revenues. Selling, general and administrative expenses rose 22.4% to $181.1 million. Research and development expenses totaled $21.8 million, up 8.9% year over year. Adjusted operating profit amounted to $59.2 million compared with $42.8 million in the corresponding period of 2024. The ad...

Penumbra, Inc. PEN reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.18 compared with 85 cents in the year-ago quarter. The figure surpassed the Zacks Consensus Estimate by 5.36%. GAAP earnings were $1.20 per share compared with 86 cents in the prior-year period. For the full year, adjusted EPS came in at $3.84, up 82.9% year over year. Penumbra registered revenues of $385.4 million in the reported quarter, up 22.1% year over year on a reported basis and 20.9% at constant exchange rate or CER. The figure topped the Zacks Consensus Estimate by 6.74%. For the full year, revenues were $1.40 billion, reflecting a 17.5% rise from the year-ago period (16.9% at CER). Since the Feb. 25 announcement, PEN shares have risen 1.7%, closing at $344.39 on Friday. The company reports under two geographical segments — the United States and International. PEN recorded revenues of $299.1 million (77.6% total revenues) in the United States, up 20.6% year over year on a reported basis. Revenues in the International segment increased 27.7% on a reported basis (up 20.9% in CER) to $86.3 million (22.4% of total revenues). Penumbra, Inc. price-consensus-eps-surprise-chart | Penumbra, Inc. Quote The company currently reports its product revenues under two categories — Thrombectomy, and Embolization and Access. The company registered revenues of $254.7 million from sales of Thrombectomy products, up 15.7% on a reported basis and 14.7% at CER. Sales of Embolization and Access products totaled $130.7 million, up 22.1% on a reported basis and 20.9% at CER. In the reported quarter, Penumbra’s gross profit improved 24.4% year over year to $262.1 million. The gross margin expanded 123 basis points (bps) to 68% despite a 17.6% rise in the cost of revenues. Selling, general and administrative expenses rose 22.4% to $181.1 million. Research and development expenses totaled $21.8 million, up 8.9% year over year. Adjusted operating profit came in at $59.2 million compared with $42.8 million in the comparable 2024 period. The adjusted operating margin expanded 181 bps year over year to 13.4%. Penumbra exited the fourth quarter of 2025 with cash and marketable investments of $544.8 million compared with $340.1 million at the end of 2024. In January 2026, Penumbra announced a definitive agreement to be acquired by Boston Scientific in a cash and stock transaction, valuing the com...

Penumbra (PEN) came out with quarterly earnings of $1.18 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $0.97 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +5.36%. A quarter ago, it was expected that this medical device maker would post earnings of $0.9 per share when it actually produced earnings of $0.97, delivering a surprise of +7.78%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Penumbra, which belongs to the Zacks Medical - Instruments industry, posted revenues of $385.39 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 6.74%. This compares to year-ago revenues of $315.52 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Penumbra shares have added about 9.2% since the beginning of the year versus the S&P 500's gain of 0.7%. While Penumbra has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Penumbra was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stoc...

ALAMEDA, Calif. (AP) — ALAMEDA, Calif. (AP) — Penumbra Inc. (PEN) on Wednesday reported fourth-quarter net income of $47.3 million. The Alameda, California-based company said it had net income of $1.20 per share. Earnings, adjusted for non-recurring gains, were $1.18 per share. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $1.12 per share. The medical device maker posted revenue of $385.4 million in the period. For the year, the company reported profit of $177.7 million, or $4.52 per share. Revenue was reported as $1.4 billion. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PEN at https://www.zacks.com/ap/PEN

For the quarter ended December 2025, Penumbra (PEN) reported revenue of $385.39 million, up 22.1% over the same period last year. EPS came in at $1.18, compared to $0.97 in the year-ago quarter. The reported revenue represents a surprise of +6.74% over the Zacks Consensus Estimate of $361.04 million. With the consensus EPS estimate being $1.12, the EPS surprise was +5.36%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Penumbra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Geographic Revenue- United States: $299.05 million compared to the $289.07 million average estimate based on three analysts. The reported number represents a change of +20.6% year over year. Geographic Revenue- International: $86.33 million compared to the $73.9 million average estimate based on three analysts. The reported number represents a change of +27.7% year over year. Revenue- Embolization and Access - International: $34.7 million versus $31.06 million estimated by three analysts on average. Revenue- Thrombectomy - International: $51.63 million compared to the $42.84 million average estimate based on three analysts. Revenue- Embolization and Access - United States: $95.99 million compared to the $80.72 million average estimate based on three analysts. Revenue- Thrombectomy - United States: $203.07 million versus $208.34 million estimated by three analysts on average. Revenue- Embolization and Access: $130.69 million versus the three-analyst average estimate of $111.78 million. The reported number represents a year-over-year change of +37%. Revenue- Thrombectomy: $254.7 million compared to the $251.19 million average estimate based on three analysts. The reported number represents a change of +15.7% year over year. View all Key Company Metrics for Penumbra here>>> Shares of Penumbra have returned -5.5% over the past month versus the Zacks S&P 5...

ALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025. Financial Highlights: Revenue of $385.4 million for the fourth quarter of 2025, an increase of 22.1% or 20.9% in constant currency1, compared to the fourth quarter of 2024. Revenue of $1,403.7 million for the full year 2025, an increase of 17.5% or 16.9% in constant currency1, compared to the full year 2024. U.S. Thrombectomy revenue of $203.1 million for the fourth quarter of 2025, an increase of 12.4% compared to the fourth quarter of 2024. U.S. Thrombectomy revenue of $771.5 million for the full year 2025, an increase of 19.3% compared to the full year 2024. Income from operations of $59.2 million or operating margin of 15.4% for the fourth quarter of 2025. Income from operations of $189.2 million or operating margin of 13.5% for the full year 2025. Net income of $47.3 million and adjusted EBITDA1 of $79.1 million or net income margin of 12.3% and adjusted EBITDA margin1 of 20.5% for the fourth quarter of 2025. Net income of $177.7 million and adjusted EBITDA1 of $266.8 million or net income margin of 12.7% and adjusted EBITDA margin1 of 19.0% for the full year 2025. Fourth Quarter 2025 Financial Results Total revenue increased to $385.4 million for the fourth quarter of 2025 compared to $315.5 million for the fourth quarter of 2024, an increase of 22.1%, or 20.9% in constant currency1. The United States represented 77.6% of total revenue and international represented 22.4% of total revenue for the fourth quarter of 2025. Revenue from the U.S. increased 20.6% while revenue from our international regions increased 27.7%, or 21.9% in constant currency1. Revenue from sales of our global thrombectomy products grew to $254.7 million in the fourth quarter of 2025, an increase of 15.7%, or 14.7% in constant currency1 over the same period a year ago, driven primarily by the sales of our U.S. thrombectomy products which increased by 12.4%. Revenue from sales of our global embolization and access products grew to $130.7 million in the fourth quarter of 2025, an increase of 37.0%, or 35.2% in constant currency1 from the same period a year ago, driven primarily by our U.S. embolization and access products which increased by 42.7% from the same period a year a...